| Ytd | -29.10% | |
| 1y | 171.10% |
| Open | 48.80 | Prev Close | 49.35 | Low | 48.80 | High | 50.00 | Mkt Cap | 2.84B |
| Vol | 169.02K | Avg Vol | 797.91K | EPS | -1.57 | P/E | -31.43 | Forward P/E | -27.60 |
| Beta | -1.50 | Short Ratio | 6.71 | Inst. Own | 96.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 44.30 | 200-d Avg | 51.14 | 1yr Est | 104.59 |
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk an
Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc
Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of
Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in develo
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Sc
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinic
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking T
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on meta
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targ
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centere
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., L
Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.35) per share which met the an
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight lo
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin
Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR)
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company develo
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin
Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101
Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored AD
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment,
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with
https://www.barrons.com/articles/structure-therapeutics-weight-loss-pill-trial-stock-93dba470
Structure Therapeutics' Phase 2 ACCESS II trial shows up to 16.3% placebo-adjusted weight loss f
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market O
Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.36) per share which beat the a
https://www.axios.com/pro/biotech-deals/2026/01/30/structure-therapeutics-pharmas-next-buyout-glp1